micro-community-banner
Profile Image
  • Add Media
  • Saved

1yr
The Future of Care in Obesity and Cardiovascular Disease: Emerging Strategies and Considerations

As the prevalence of obesity continues to rise globally, its impact on cardiovascular disease (CVD) has become a significant public health concern. The interplay between obesity and cardiovascular health necessitates a comprehensive approach that integrates lifestyle modifications, pharmacotherapy, and innovative care models.

Emerging research emphasizes the importance of addressing obesity not just as a standalone condition but as a critical risk factor for CVD. Multi-disciplinary care teams are essential in developing personalized treatment plans that encompass dietary interventions, physical activity, and psychological support. Furthermore, advancements in technology, such as telehealth and digital monitoring tools, are revolutionizing how healthcare providers engage with patients, enabling more frequent and meaningful interactions.

A pivotal area of focus is the development of evidence-based guidelines that outline best practices for managing patients with obesity and CVD. Collaborative efforts between primary care providers, cardiologists, and endocrinologists will be crucial in ensuring that patients receive comprehensive care that addresses all aspects of their health.

As we look to the future, what innovative strategies are you implementing to improve outcomes for patients with obesity and cardiovascular disease? How do you foresee the integration of technology influencing patient management in this space?

Profile Image
  • 1yr
    glp-1 and sglt2 help correct blood sugar,also reduce kidney disease which reduces heart disease ,with significant weight loss which helps to reduce blood pressure and fatty liver disease
  • 1yr
    Marker improvements in treatment compared to few years ago specially w newest GLP1 and GLPand GPIand SGLT2. I wish insurances approved in non diabetic pts. I see a good response in Show More

Show More Comments

  • Saved

1yr
Treatment of Eating Disorders: Current Status, Challenges, and Future Directions - PubMed

Treatment of Eating Disorders: Current Status, Challenges, and Future Directions - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38211625/

Specific psychological treatments have demonstrated efficacy and represent the first-line approaches recommended for anorexia nervosa, bulimia nervosa, and binge-eating disorder. Unfortunately, many patients, particularly those with anorexia nervosa, do not...

Psychological treatments are first-line for eating disorders, but efficacy remains limited. Pharmacologic options are scarce. Emerging adaptive treatment designs offer clinical insights and potential models for improved future therapies.

Profile Image
  • Saved

1yr
Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial - PubMed

Assessing the efficacy of tocotrienol-rich fraction vitamin E in obese children with non-alcoholic fatty liver disease: a single-blind, randomized clinical trial - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39160468/

The study has been registered with the International Clinical Trial Registry under reference number (NCT05905185) retrospective registration on (15/06/2023).

A study on 29 children with obesity and NAFLD found that vitamin E enriched with tocotrienol (TRF) reduced DNA damage, inflammatory cytokines, and liver markers, suggesting its potential as a safe treatment for NAFLD.

Profile Image
  • Saved

1yr
Effects of Metabolic Dysfunction-Associated Steatotic Liver Disease on Bone Density and Fragility Fractures: Associations and Mechanisms - PubMed

Effects of Metabolic Dysfunction-Associated Steatotic Liver Disease on Bone Density and Fragility Fractures: Associations and Mechanisms - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38740429/

Metabolic dysfunction-associated steatotic liver disease (MASLD) has profound adverse effects on bone health and homeostasis. MASLD appears to be associated with changes in bone mineral density (BMD) and fracture rate....

MASLD impacts bone health, reducing BMD and increasing fragility fractures in adults, especially elderly Asian men, due to disrupted bone remodeling, insulin resistance, inflammation, and comorbidities like obesity and diabetes.

Profile Image
  • Saved

1yr
Diet, exercise, and supplements: what is their role in the management of the metabolic dysfunction-associated steatotic liver disease in children? - PubMed

Diet, exercise, and supplements: what is their role in the management of the metabolic dysfunction-associated steatotic liver disease in children? - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38519764/

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease (NAFLD), is the main cause of chronic liver disease in children and adolescents. Indeed, epidemiological studies have...

Pediatric MASLD, affecting up to 40% of children with obesity, primarily responds to lifestyle interventions like diet and exercise; studies highlight benefits but lack consensus on optimal approaches, warranting further research.

Profile Image